visualizations
Sonpavde, Guru, MD
Overview
overview
- Guru P. Sonpavde, MD serves as the Medical Director of Genitourinary (GU) Oncology, Assistant Director of the Clinical Research Unit and Christopher K. Glanz Chair for Bladder Cancer Research at the AdventHealth Cancer Institute. Previously, he was Bladder Cancer Director at the Dana-Farber Cancer Institute and Associate Professor of Medicine at Harvard Medical School from 2017-2022, GU Oncology Director and Associate Professor of Medicine at the University of Alabama at Birmingham from 2012 to 2017 and practiced from 2004 to 2012 at Texas Oncology. His focus is drug development and translational research to cure GU cancers, which have led to approximately 500 publications. He is a member of Southwest Oncology Group, Scientific Advisory Board of the Bladder Cancer Advocacy Network (BCAN), and the Bladder Cancer Task Force of U.S. NCI GU Steering Committee. He was cited in TIME magazine regarding his participation in clinical trials in August 2022.
Affiliation
Member of
-
Clinical Program
-
Research Department
Publications
Most Recent Publications
-
2024Vaccine approaches to treat urothelial cancer. HUMAN VACCINES & IMMUNOTHERAPEUTICS.Full Text via DOI: 10.1080/21645515.2024.2379086 PMID: 39043175
-
2024Impact of Angiotensin Converting Enzyme Inhibitors on Pathologic Complete Response With Neoadjuvant Chemotherapy for Muscle Invasive Bladder Cancer. CLINICAL GENITOURINARY CANCER. 22.Full Text via DOI: 10.1016/j.clgc.2024.102143 PMID: 39032202
-
2024Evaluation of American Joint Committee on Cancer and alternative tumour classification systems for primary penile squamous cell carcinoma. BRITISH JOURNAL OF DERMATOLOGY. I104-I105.Full Text via DOI: 10.1093/bjd/ljae090.218
-
2024New Therapeutic Horizons for Advanced or Metastatic Penile Cancer. UROLOGIC CLINICS OF NORTH AMERICA. 51:367-376.Full Text via DOI: 10.1016/j.ucl.2024.03.005 PMID: 38925739
-
2024Factors predictive of recurrence, metastasis and death in node-negative penile squamous cell carcinoma: A retrospective multicentre cohort study. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY.Full Text via DOI: 10.1111/jdv.20093 PMID: 38842227
-
2024The evolving treatment landscape of metastatic urothelial cancer. NATURE REVIEWS UROLOGY.Full Text via DOI: 10.1038/s41585-024-00872-0 PMID: 38702396
-
2024Clinical outcomes and safety of immune checkpoint inhibitors in patients with solid tumors and paraneoplastic syndromes. JOURNAL FOR IMMUNOTHERAPY OF CANCER. 12.Full Text via DOI: 10.1136/jitc-2023-008724 PMID: 38448038
-
2024Unlocking precision oncology with FGFR inhibition in urothelial carcinoma. ANNALS OF ONCOLOGY. 150-153.Full Text via DOI: 10.1016/j.annonc.2023.11.006 PMID: 37981237
-
2024Circulating tumor DNA as a Predictive and Prognostic Biomarker in the Perioperative Treatment of Muscle-invasive Bladder Cancer: A Systematic Review. EUROPEAN UROLOGY ONCOLOGY. 44-52.Full Text via DOI: 10.1016/j.euo.2023.05.012 PMID: 37330413
-
2024Comprehensive multiplexed autoantibody profiling of patients with advanced urothelial cancer. JOURNAL FOR IMMUNOTHERAPY OF CANCER. 12.Full Text via DOI: 10.1136/jitc-2023-008215 PMID: 38309723
-
2024The Double Antibody Drug Conjugate (DAD) phase I trial: sacituzumab govitecan plus enfortumab vedotin for metastatic urothelial carcinoma. ANNALS OF ONCOLOGY. 35:91-97.Full Text via DOI: 10.1016/j.annonc.2023.09.3114 PMID: 37871703
-
2024Approaches to Treating High Risk and Advanced Renal Cell Carcinoma (RCC): Key Trial Data That Impacts Treatment Decisions in the Clinic. RESEARCH AND REPORTS IN UROLOGY. 16:161-176.Full Text via DOI: 10.2147/RRU.S457287 PMID: 39072353
-
2024Total Margin Control Is Superior to Traditional Margin Assessment for Treatment of Low-Stage Penile Squamous Cell Carcinoma. JOURNAL OF UROLOGY. 211:90-100.Full Text via DOI: 10.1097/JU.0000000000003736 PMID: 37788015
-
2023Correlation of safety and efficacy in atezolizumab therapy across indications. ANNALS OF ONCOLOGY. S1079-S1079.Full Text via DOI: 10.1016/j.annonc.2023.09.815
-
2023Predictors of Efficacy of Immune Checkpoint Inhibitors in Patients With Advanced Urothelial Carcinoma: A Systematic Review and Meta-Analysis. CLINICAL GENITOURINARY CANCER. 574-583.Full Text via DOI: 10.1016/j.clgc.2023.05.017 PMID: 37419854
-
2023Safety and efficacy of immune checkpoint inhibitors in advanced penile cancer: report from the Global Society of Rare Genitourinary Tumors. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE.Full Text via DOI: 10.1093/jnci/djad155 PMID: 37563779
-
2023Comparing cardiovascular adverse events in cancer patients: A meta-analysis of combination therapy with angiogenesis inhibitors and immune checkpoint inhibitors versus angiogenesis inhibitors alone. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY.Full Text via DOI: 10.1016/j.critrevonc.2023.104059 PMID: 37353178
-
2023Real-world treatment patterns and clinical outcomes with first-line therapy in patients with locally advanced/metastatic urothelial carcinoma by cisplatin-eligibility. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS. 41:3.57e+13-3.57e+23.Full Text via DOI: 10.1016/j.urolonc.2023.03.012 PMID: 37208230
-
2023Muscle invasive bladder cancer: where is the field headed?. EXPERT OPINION ON BIOLOGICAL THERAPY.Full Text via DOI: 10.1080/14712598.2023.2238607 PMID: 37477127
-
2023Safety and Activity of Immune Checkpoint Inhibitors in People Living With HIV and Cancer: A Real-World Report From the Cancer Therapy Using Checkpoint Inhibitors in People Living With HIV-International (CATCH-IT) Consortium. JOURNAL OF CLINICAL ONCOLOGY. 41:3712-+.Full Text via DOI: 10.1200/JCO.22.02459 PMID: 37192435
-
2023Precision Medicine to Treat Urothelial Carcinoma-The Way Forward. CANCERS.Full Text via DOI: 10.3390/cancers15113024 PMID: 37296985
-
2023Antibody-Drug Conjugates in the Treatment of Urothelial Cancer. BIODRUGS. 505-520.Full Text via DOI: 10.1007/s40259-023-00606-5 PMID: 37256534
-
2023Emerging monoclonal antibody therapies in the treatment of metastatic urothelial carcinoma. EXPERT OPINION ON EMERGING DRUGS. 17-26.Full Text via DOI: 10.1080/14728214.2023.2186398 PMID: 36882977
-
2023Comparative real-world survival outcomes of muscle-invasive bladder cancer treated with bladder-only vs. whole-pelvis concurrent chemoradiation. CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL. 18:16-23.Full Text via DOI: 10.5489/cuaj.8386 PMID: 37931278
-
2022Therapeutic Landscape Beyond Immunotherapy in Advanced Urothelial Carcinoma: Moving Past the Checkpoint. DRUGS.Full Text via DOI: 10.1007/s40265-022-01802-3 PMID: 36441503
Background
Full Name
- Guru Sonpavde, MD
Education
- University of Madras
Residency
- Internal Medicine at Nassau County Medical Center
Fellowship
- Hematology & Oncology at Indiana University School of Medicine
Board Certification
- Medical Oncology: The American Board of Internal Medicine Internal Medicine: The American Board of Internal Medicine
Contact
primary email
- Research.Institute@AdventHealth.com